The SHIFT study (The Systolic Heart failure treatment with the I_f inhibitor ivabradine Trial) and its role in the treatment of heart failure

Česká verzia

Authors: J. Vítovec ¹; J. Špinar ²
Authors place of work: I. interní kardioangiologická klinika, LF MU a FN u sv. Anny, Brno ¹; Interní kardiologická klinika, LF MU a FN Brno-Bohunice ²
Published in the journal: Kardiol Rev Int Med 2010, 12(3): 125-127

Summary

The SHIFT study compared the effect of ivabradine with placebo in 6 558 patients with heart failure of ischemic or non-ischemic aetiology, NYHA II–IV, with a heart rate > 70 bpm, who had an optimal management of heart failure, including beta-blockers. The results showed significant reduction in the risk of the primary endpoint – decrease in hospitalization for heart failure and cardiovascular mortality by 18% in total for ivabradine compared to placebo. Similarly, there was a reduction in the risk of death due to heart failure by 26% in the active treatment group. Ivabradine was as well tolerated as placebo.

Keywords:
heart failure – ivabradine – heart rate

Zdroje

1. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807–816.

2. Fox K, Borer JS, Camm AJ et al. Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823–830.

3. Thackray SD, Ghosh JM, Wright GA et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 2006; 152: 713.e9–13.

4. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008; 31: 95–107.

5. Swedberg K, Komajda M, Böhm M et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010; 12: 75–81.

6. Swedberg K, Komajda M, Böhm M et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61198-1/fulltext]. Published online August 29, 2010 DOI.